{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:48:47Z","timestamp":1761238127340,"version":"3.37.3"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1124\/dmd.114.059675","type":"journal-article","created":{"date-parts":[[2014,9,13]],"date-time":"2014-09-13T07:36:44Z","timestamp":1410593804000},"page":"2023-2032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry"],"prefix":"10.1016","volume":"42","author":[{"given":"Susanna","family":"Tse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta","family":"Raje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Shishikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Scott","family":"Obach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.059675_bib1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1017\/S1461145710000659","article-title":"Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats","volume":"13","author":"Arnt","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"10.1124\/dmd.114.059675_bib2","first-page":"S510","article-title":"The effects of a single dose administration of SAM-531, a 5-HT6 antagonist, on sleep electroencephalogram (EEG) and quantitative wake EEG (QEEG) in healthy subjects","volume":"6","author":"Baird-Bellaire","year":"2010","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1124\/dmd.114.059675_bib3","first-page":"S311","article-title":"Safety, tolerability, and preliminary efficacy of SAM-531, a 5HT6 antagonist, in subjects with mild-to-moderate Alzheimer\u2019s disease: results from a phase 2A study","volume":"6","author":"Brisard","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1124\/dmd.114.059675_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0028-3932(00)00149-4","article-title":"Brain regions involved in prospective memory as determined by positron emission tomography","volume":"39","author":"Burgess","year":"2001","journal-title":"Neuropsychologia"},{"key":"10.1124\/dmd.114.059675_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","article-title":"5-HT(6) receptor and cognition","volume":"11","author":"Codony","year":"2011","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1124\/dmd.114.059675_bib6","first-page":"S548","article-title":"SAM-531, N,N-dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, a novel serotonin-6 receptor antagonist with preclinical pro-cognitive efficacy","volume":"6","author":"Comery","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1124\/dmd.114.059675_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2133\/dmpk.24.511","article-title":"Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS)","volume":"24","author":"C\u00f6mezo\u011flu","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.114.059675_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.114.059675_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bjp.0703288","article-title":"In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate","volume":"130","author":"Dawson","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.114.059675_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.npp.1300332","article-title":"The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats","volume":"29","author":"Foley","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/dmd.114.059675_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/1389200003339054","article-title":"Accelerator mass spectrometry in pharmaceutical research and development\u2014a new ultrasensitive analytical method for isotope measurement","volume":"1","author":"Garner","year":"2000","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.114.059675_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4155\/bio.10.6","article-title":"Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data","volume":"2","author":"Garner","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1124\/dmd.114.059675_bib13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1124\/dmd.30.7.823","volume":"30","author":"Garner","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059675_bib14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1586\/ern.09.51","article-title":"The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer\u2019s disease","volume":"9","author":"Geldenhuys","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1124\/dmd.114.059675_bib15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1124\/dmd.111.039339","article-title":"A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry","volume":"39","author":"Graham","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059675_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1423-0127-16-54","article-title":"Recent advances in biomedical applications of accelerator mass spectrometry","volume":"16","author":"Hah","year":"2009","journal-title":"J Biomed Sci"},{"key":"10.1124\/dmd.114.059675_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059675_bib18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1124\/mol.64.6.1295","article-title":"Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling","volume":"64","author":"Hirst","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.114.059675_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.114.059675_bib20","first-page":"642","article-title":"5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia","volume":"11","author":"Johnson","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1124\/dmd.114.059675_bib21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.4155\/bio.10.87","article-title":"Addressing metabolite safety during first-in-man studies using \u00b9\u2074C-labeled drug and accelerator mass spectrometry","volume":"2","author":"Lappin","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1124\/dmd.114.059675_bib22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1517\/17425255.4.8.1021","article-title":"Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics","volume":"4","author":"Lappin","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.114.059675_bib23","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/sj.npp.1300777","article-title":"The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat","volume":"30","author":"Lieben","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/dmd.114.059675_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-013-2183-0","article-title":"Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry","volume":"72","author":"Lin","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.114.059675_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1124\/jpet.103.056002","article-title":"An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning","volume":"307","author":"Lindner","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.059675_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ddr.20293","article-title":"5-HT6 antagonists as potential treatment for cognitive dysfunction","volume":"70","author":"Liu","year":"2009","journal-title":"Drug Dev Res"},{"key":"10.1124\/dmd.114.059675_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-384976-2.00001-0","article-title":"5-HT6 medicinal chemistry","volume":"94","author":"Liu","year":"2010","journal-title":"Int Rev Neurobiol"},{"key":"10.1124\/dmd.114.059675_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study","volume":"26","author":"Maher-Edwards","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1124\/dmd.114.059675_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/156720510791383831","article-title":"Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer\u2019s disease","volume":"7","author":"Maher-Edwards","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"10.1124\/dmd.114.059675_bib30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11064-011-0684-y","article-title":"Distribution of serotonin receptor of type 6 (5-HT6) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study","volume":"37","author":"Marazziti","year":"2012","journal-title":"Neurochem Res"},{"key":"10.1124\/dmd.114.059675_bib31","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1460-9568.2006.05003.x","article-title":"Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release","volume":"24","author":"Marcos","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1124\/dmd.114.059675_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-12-385902-0.00007-3","article-title":"5-HT6 receptor ligands as antidementia drugs","volume":"96","author":"Mitchell","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1124\/dmd.114.059675_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00213-011-2518-7","article-title":"The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats","volume":"220","author":"Mohler","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.114.059675_bib34","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jps.10091","volume":"91","author":"Nakajima","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.114.059675_bib35","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1073\/pnas.93.20.11280","article-title":"General and specific brain regions involved in encoding and retrieval of events: what, where, and when","volume":"93","author":"Nyberg","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.114.059675_bib36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/jm021085c","article-title":"Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist","volume":"46","author":"Riemer","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.114.059675_bib37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s002210050592","article-title":"Electrophysiological localization of brain regions involved in perceptual memory","volume":"123","author":"Reinvang","year":"1998","journal-title":"Exp Brain Res"},{"key":"10.1124\/dmd.114.059675_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0006-8993(02)02360-0","article-title":"The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585","volume":"934","author":"Roberts","year":"2002","journal-title":"Brain Res"},{"key":"10.1124\/dmd.114.059675_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156802610790411036","article-title":"5-HT6 receptor antagonists as potential therapeutics for cognitive impairment","volume":"10","author":"Ross\u00e9","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.114.059675_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-003-1683-8","article-title":"Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders","volume":"174","author":"Roth","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.114.059675_bib41","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1021\/ac800174j","article-title":"Subattomole sensitivity in biological accelerator mass spectrometry","volume":"80","author":"Salehpour","year":"2008","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.114.059675_bib42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0091270005280051","article-title":"The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers","volume":"45","author":"Sarapa","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059675_bib43","series-title":"The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics","first-page":"495","article-title":"5-HT receptors as targets for the treatment of cognitive deficits in schizophrenia","author":"Schreiber","year":"2006"},{"key":"10.1124\/dmd.114.059675_bib44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","article-title":"5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer\u2019s disease","volume":"5","author":"Upton","year":"2008","journal-title":"Neurotherapeutics"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624114869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624114869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.059675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:36:51Z","timestamp":1739907411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624114869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0090955624114869"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.059675","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.059675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}